Meningiomas, neoplasms of mesodermal-arachnoid origin, are the most common primary intracranial and spinal tumors. About 80% of them show benign features and are amenable to surgical resection alone. 20%, however, require extensive multimodal treatment (repeat surgery, radiotherapy, or systemic chemotherapy) and can recur nonetheless. Currently, histopathological grade is the main predictor of meningioma behavior, with most grade I (called ‘benign’) tumors having a nonmalignant course; on the other hand, grade II (‘atypical’) and III (‘anaplastic’) meningiomas are often more aggressive and recur. The current WHO classification relies on histomorphological features to sub-classify meningiomas into 15 subtypes, nine for grade I and three each for grade II and III. To complement and improve an all histology-based classification, new genomics- and methylation-based approaches are emerging. Currently, there is an unmet need given the absence of a comprehensive classification system with prognostic information. Such a necessity is strengthened by the diverse fate that some grade I meningiomas have. A vast majority never recurs or progresses following surgical resection. However, a small subset recurs locally and can progress to a higher grade.
Pediatric meningiomas are extremely rare tumors that account for about 2% of all meningiomas. It is thought that the biology of these tumors is different from that of their adult counterpart although the details of these differences remain largely unknown. Interestingly, pediatric meningiomas present most often a more aggressive histological phenotype but the molecular drivers of this aggressive phenotype are not known. In comparison, adult meningiomas are in majority benign tumors.
What are the goals of this project?
Our project aims at deciphering the molecular characteristics of pediatric meningiomas through the analysis of whole genome sequencing data (RNAseq, WGS) and comparing the genetic of the pediatric tumors to the adult meningiomas.
What is the impact of this project?
This project will lead to a better understanding of pediatric meningiomas biology and therefore most likely will lead to the establishment of therapies that will be more adequately designed for the pediatric population.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas
Bo Zhang will be the bioinformatician on this project.
Nadia Dahmane, PhD
Dr. Dahmane’s current research focuses a group of proteins called transcription factors that regulate how different genes are expressed during both brain development and brain cancer progression. Her laboratory has identified a critical novel transcription factor protein (called RP58) that is ind
Weill Cornell Medicine Pediatric Brain & Spine Center
Adam Resnick, PhD
Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He i
Children’s Hospital of Philadelphia